Direct Oral Anticoagulant–Calibrated Heparin LRT Assay as a Rapid Alternative to an Anti‐Factor Xa Assay for Measuring Apixaban, Edoxaban, and Rivaroxaban in Patients With Non‐Valvular Atrial Fibrillation

The data that support the findings of this study are openly available in Jin-Yeong Han at ORCID, reference number ORCID: 0000-0003-0280-2739. Figure S1: Passing–Bablok regression of DOAC concentrations measured with the DOAC-calibrated Heparin LRT reagent (Y axis) against the DiXaI reagent (X axis) for apixaban (A–C), edoxaban (D–F), and rivaroxaban (G–I) at trough, peak, and all sampling points combined. The solid line represents the regression line and the dotted line indicates the line of identity (Y = X). DOAC, direct oral anticoagulants; DiXaI, direct factor Xa inhibitor reagent; LRT, liquid reagent technology. Table S1: Baseline characteristics and reagent lower limits of quantification by DOAC. Both reagents were calibrated with drug-specific DOAC calibrators. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.